The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Initial results from MagnetisMM-30: elranatamab plus iberdomide in RRMM
Attaya Suvannasankha, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, discusses the initial report of safety and efficacy from the Phase Ib MagnetisMM-30 trial (NCT06215118), which combined elranatamab with iberdomide in patients with relapsed/refractory multiple myeloma (RRMM). Dr Suvannasankha reports promising results, with an overall response rate of 95.5% and a manageable safety profile. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
